Skip to main content

Together we are beating cancer

Donate now

Research and trials

Showing 12 out of 1704 results

Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers... Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers...

by Phil Prime | In depth | 13 December 2021

13 December 2021

Patrick and Pam

How exactly do you create an exhibition looking at the hugely complex and emotive subject of cancer? You do exactly what the Science Museum has done in its superb exhibition, which I had the pleasure of attending last month. How exactly do you create an exhibition looking at the hugely complex and emotive subject of cancer? You do exactly what the Science Museum has done in its superb exhibition, which I had the pleasure of attending last month.

by Patrick McGuire | Analysis | 24 November 2021

24 November 2021

We speak with two science communication masters about the benefits, ethics and sheer fun of communicating your research to the public. We speak with two science communication masters about the benefits, ethics and sheer fun of communicating your research to the public.

by Phil Prime | In depth | 22 November 2021

22 November 2021

On LGBTQ+ STEM day, we hear from two Cancer Research UK scientists on the power of diversity and why bringing your full self to your research is so important… On LGBTQ+ STEM day, we hear from two Cancer Research UK scientists on the power of diversity and why bringing your full self to your research is so important…

by Phil Prime | In depth | 18 November 2021

18 November 2021

This entry is part 6 of 10 in the series Diversity in research
%postcontent%
Some of the In2scienceUK mentors and mentees

We’ve partnered with In2science UK, an organisation that promotes diversity in STEM, to sponsor 10 young people through a mentoring programme. We’ve partnered with In2science UK, an organisation that promotes diversity in STEM, to sponsor 10 young people through a mentoring programme.

by Mae De Los Santos | In depth | 16 November 2021

16 November 2021

This entry is part 7 of 10 in the series Diversity in research
%postcontent%
Eithne Costello

Professor Eithne Costello on the challenges of ambitious trials, the evolution of early detection as a field in its own right and why a guiding framework is all important. Professor Eithne Costello on the challenges of ambitious trials, the evolution of early detection as a field in its own right and why a guiding framework is all important.

by Phil Prime | Interview | 12 November 2021

12 November 2021

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials - we tell the story from discovery to translation. Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials - we tell the story from discovery to translation.

by Cancer Research UK | In depth | 5 November 2021

5 November 2021

We caught up with Director of Research, Dr Catherine Elliott, to talk pandemic recovery, research careers and the role of curiosity in a goal driven scientific environment We caught up with Director of Research, Dr Catherine Elliott, to talk pandemic recovery, research careers and the role of curiosity in a goal driven scientific environment

by Phil Prime | Interview | 2 November 2021

2 November 2021

Barrett's oesophagus under the microscope

Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now. Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now.

by Harry Jenkins | Analysis | 25 October 2021

25 October 2021

3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021

We speak to Professor Shankar Balasubramanian about his work on NGS, his incredible translational journey and the power of the pub… We speak to Professor Shankar Balasubramanian about his work on NGS, his incredible translational journey and the power of the pub…

by Phil Prime | Interview | 15 October 2021

15 October 2021